Skip to main content
Kinarus Therapeutics Holding AG logo

Kinarus Therapeutics Holding AG — Investor Relations & Filings

Ticker · KNRS ISIN · CH1330780979 LEI · 506700VDL70GGMHR5758 SW Manufacturing
Open in API
Filings indexed 68 across all filing types
Latest filing 2025-03-27 Investor Presentation
Country CH Switzerland
Listing SW KNRS

About Kinarus Therapeutics Holding AG

https://www.curatis.com/

Formerly Kinarus Therapeutics Holding AG, the company now operates as Curatis Holding AG, a specialty pharmaceutical company focused on the acquisition, development, and commercialization of innovative medicines for rare and specialty care diseases. The company's operations are divided into two segments. The distribution business acquires, licenses, and distributes third-party medicines for orphan and specialty diseases. The development business advances a pipeline of novel drug candidates, prioritizing compounds with existing safety and efficacy data to accelerate development. Key development programs target conditions such as peritumoral brain edema, severe migraine with aura, and medication overuse headache.

Recent filings

Filing Released Lang Actions
Investor Presentation
Investor Presentation Classification · 98% confidence The document text contains extensive information about the company's history, management team (Board of Directors, Executive Management, Advisory Board), business focus (niche and rare diseases), distribution network, and detailed pipeline projects (C-PTBE-01, C-AM-01, C-MOH-01, KIN001) including development stages, mechanism of action, peak sales potential, and intellectual property status. It also includes a small financial table comparing FY 2024 and FY 2023 figures in mCHF. This structure—introducing the company, detailing governance, outlining strategy, and presenting a detailed R&D pipeline with future outlook—is characteristic of an Investor Presentation (IP) or a comprehensive Annual Report (10-K). Given the focus on strategy, pipeline deep-dive, and management structure, it strongly aligns with an Investor Presentation (IP). It is not a short announcement (RPA/RNS), nor is it a formal regulatory filing like a 10-K, but rather a presentation designed for investors.
2025-03-27 English
Annual Report 2024
Annual Report Classification · 100% confidence The document is titled 'Annual Report' and contains comprehensive sections including a letter to shareholders, business review, corporate governance, compensation report, and consolidated financial statements for the year ended 31 December 2024. It is a full-length report detailing the company's annual performance and financial position, fitting the definition of a 10-K (Annual Report). FY 2024
2025-03-27 English
Curatis Announces Formation of Distinguished Advisory Board
Board/Management Information Classification · 95% confidence The document is a 'MEDIA RELEASE' from Curatis Holding announcing the formation of a Distinguished Advisory Board comprised of medical and scientific experts. This type of announcement details changes in the company's strategic guidance structure, involving key personnel additions (advisors). This aligns best with the 'Board/Management Information' category, which covers changes in the company's board or senior management structure, extending logically to key advisory bodies that guide strategy. It is not a formal financial filing (like 10-K, ER, IR), nor is it a transcript, dividend notice, or legal update. Therefore, MANG (Board/Management Information) is the most appropriate classification.
2025-03-12 English
Curatis Announces Formation of Distinguished Advisory Board
Board/Management Information Classification · 95% confidence The document is a 'MEDIA RELEASE' from Curatis Holding announcing the formation of a Distinguished Advisory Board comprised of medical and scientific experts. This type of announcement details changes in the company's strategic guidance structure, involving key personnel additions (advisors). This aligns best with the 'Board/Management Information' category, which covers changes in the company's board or senior management structure, extending logically to key advisory bodies that guide strategy. It is not a formal financial filing (like 10-K, ER, IR), nor is it a transcript, dividend notice, or legal update. Therefore, MANG (Board/Management Information) is the most appropriate classification.
2025-03-11 English
Curatis Announces Formation of Distinguished Advisory Board
Board/Management Information Classification · 99% confidence The document is a formal announcement titled 'MEDIA RELEASE' from Curatis Holding AG, dated March 11, 2025. The core content announces the 'Formation of Distinguished Advisory Board' and details the qualifications of the new members. This type of announcement concerns changes in the company's strategic guidance structure, involving high-level personnel/advisors, but it is not a change in the Board of Directors itself (which would be MANG). It is also not a standard regulatory filing like 10-K, ER, or IR. Since it relates to the strategic direction and key personnel advising the company, it fits best under Board/Management Information (MANG) as it pertains to the governance and strategic leadership structure, even if the individuals are advisors rather than voting directors. However, given the specific definitions, MANG is for 'changes in the company's board of directors or senior management.' Since this is an *Advisory Board*, which is distinct from the formal Board of Directors or Senior Management, and there is no better fit, I must evaluate the closest category. Announcements about key strategic appointments or advisory bodies often fall under general management/governance updates. Given the options, MANG is the closest fit for significant personnel/leadership structure changes, although 'Governance Information' (CGR) is also plausible. Since the focus is on the *people* guiding management strategy, MANG is slightly more appropriate than the broader CGR, which usually covers rules and structure. If MANG strictly means Directors/C-suite, then RNS (Regulatory Filings) would be the fallback. Given the context of high-level strategic personnel appointments, MANG is the intended classification for such leadership structure news.
2025-03-11 English
Curatis wird für C-PTBE-01 in den USA eine Biologic License beantragen - damit erhöht sich die Dauer des Marktschutzes in den USA markant im Falle einer Zulassung
Regulatory Filings Classification · 100% confidence The document is explicitly titled "MEDIA RELEASE" and announces a strategic company decision regarding the regulatory pathway (Biologic License Application - BLA) for a product (C-PTBE-01) in the USA. It details the implications for market protection and provides background on the drug development and the disease it targets. This type of announcement, which communicates a significant corporate or strategic development outside of routine financial reporting (like earnings or annual reports), is best classified as a general Regulatory Filing or a specific announcement if one fits better. Since it is not a formal financial report (10-K, IR, ER), a management discussion (MDA), or a specific insider trade (DIRS), it falls under the general regulatory/news announcement category. Given the options, 'Regulatory Filings' (RNS) is the most appropriate fallback for a general, time-sensitive corporate announcement that isn't covered by the more specific codes like DIV, CAP, or MANG. It is not an announcement of a report being published (RPA), but the news itself.
2024-11-14 German

Browse filings by year

5 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.